0.00
Evoke Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$11.00
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$18.95M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
0.00
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
EVOK
Evoke Pharma Inc
|
0.00 | 18.95M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma Leads Micro-Cap Stocks with 137.07% Return Over Past Year - MarketsMojo
Evoke Pharma Leads Micro-Cap Stocks with 149.43% Return Over Past Year - MarketsMojo
Evoke Pharma Achieves 304.41% Return, Leading Micro-Cap Stock Performance - MarketsMojo
Will Evoke Pharma Inc. stock benefit from commodity prices2025 AllTime Highs & Low Risk High Win Rate Picks - ulpravda.ru
Evoke Pharma Achieves 313.53% Return Amid Mixed Micro-Cap Performance - MarketsMojo
What technical charts say about Evoke Pharma Inc. stock - ulpravda.ru
Will Evoke Pharma Inc. stock keep outperforming rivalsJuly 2025 Fed Impact & Daily Risk Controlled Trade Plans - ulpravda.ru
Will Evoke Pharma Inc. stock gain from strong economyWeekly Profit Analysis & High Accuracy Trade Alerts - ulpravda.ru
Why Evoke Pharma Inc. stock is considered a top pickEarnings Trend Report & Fast Entry High Yield Stock Tips - ulpravda.ru
How Evoke Pharma Inc. stock performs in rate cut cyclesWeekly Trade Summary & Capital Efficiency Focused Strategies - ulpravda.ru
How Evoke Pharma Inc. stock performs in stagflationTrade Analysis Report & Stepwise Swing Trade Plans - ulpravda.ru
Evoke Pharma, Inc.Common Stock (NQ: EVOK - FinancialContent
How Evoke Pharma Inc. stock performs after earningsSwing Trading Watchlist & Free Strong Return On Assets - ulpravda.ru
Evoke Pharma Leads Pharmaceuticals Sector with 137.07% Annual Return - MarketsMojo
Operating cash flow per share of Evoke Pharma, Inc. – SWB:EV0 - TradingView — Track All Markets
Evoke Pharma Achieves 304.41% Return Amid Strong Market Performance - MarketsMojo
Evoke Pharma Achieves 313.53% Return; InnovAge Holding Up 31.39% - Markets Mojo
Evoke Pharma Achieves 313.53% Return Amid Market Volatility - Markets Mojo
Evoke Pharma Leads with 124.95% Return Among Notable Stock Performers - Markets Mojo
Evoke Pharma Leads Stock Performance with 148.87% Return in Pharmaceuticals Sector - Markets Mojo
Evoke Pharma Leads with 148.87% Return Among High-Performing Stocks - MarketsMojo
Bank Watch: Will Evoke Pharma Inc stock gain from strong economyQuarterly Earnings Report & Smart Allocation Stock Reports - moha.gov.vn
Evoke Pharma Leads Impressive Stock Returns with 126.34% Gain - MarketsMojo
Evoke Pharma Achieves 318.7% Return, Leading Pharmaceutical Stocks Performance - MarketsMojo
Evoke Pharma Leads Six-Month Stock Returns with 316.67% Gain - Markets Mojo
Evoke Pharma Achieves 316.67% Return, Leading Pharmaceutical Sector Performance - MarketsMojo
Evoke Pharma, Inc. Financial Disclosures & Filings - TradingView — Track All Markets
Evoke Pharma Leads Stocks with 124.49% Return in Pharmaceuticals Sector - Markets Mojo
Evoke Pharma Leads Six-Month Stock Returns with 298.55% Gain - MarketsMojo
Evoke Pharma Achieves 340% Return, Leading Recent Stock Performers - MarketsMojo
Evoke Pharma Leads Stock Returns with 121.77% Gain Over Past Year - MarketsMojo
Evoke Pharma Leads Stock Performance with 100.36% Return in Past Year - MarketsMojo
Evoke Pharma Leads Six-Month Stock Performance with 303.23% Return - MarketsMojo
Why Evoke Pharma Inc. stock attracts global investorsMarket Trend Summary & Verified Technical Signals - Улправда
Is Evoke Pharma Inc. stock dividend yield sustainable2025 Key Highlights & Community Consensus Trade Alerts - Улправда
Can Evoke Pharma Inc. stock sustain revenue growthAnalyst Downgrade & Low Risk Investment Opportunities - Улправда
Aug Sentiment: Is Evoke Pharma Inc. stock dividend yield sustainable2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Can Evoke Pharma Inc. stock hit analyst price targetsWeekly Trade Recap & Proven Capital Preservation Methods - DonanımHaber
Evoke Pharma Leads Stock Performance with 150% Return in Past Year - Markets Mojo
Evoke Pharma Leads Six-Month Stock Performance with 296.4% Return - Markets Mojo
Will Evoke Pharma Inc. stock benefit from infrastructure spendingJuly 2025 Snapshot & Weekly High Return Opportunities - Улправда
Is Evoke Pharma Inc. stock trading near support levels2025 Trading Volume Trends & Community Driven Trade Alerts - Улправда
Evoke Pharma and QOL Medical Announce Expiration of Tender Offer - BioSpace
Evoke Pharma acquired by QOL Medical, shares to be delisted from Nasdaq - Investing.com Canada
Evoke Pharma (NASDAQ: EVOK) clears shelf registrations following QOL Medical deal - Stock Titan
Evoke Pharma (EVOK) deregisters unsold securities following QOL Medical merger - Stock Titan
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):